Reaction
Cholangiocarcinoma reporting signals
As of the last recalculation, Cholangiocarcinoma appears in 1,465 FAERS reports alongside 31 co-occurring drug terms. The strongest observed disproportionality signal is DURVALUMAB (PRR 30.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Durvalumab | 42 | 30.2 | 30.2 |
| Gemcitabine | 70 | 26.5 | 26.5 |
| Gemcitabine Hydrochloride | 84 | 23.8 | 23.8 |
| Ursosiol | 30 | 22.4 | 22.4 |
| Ursodiol | 30 | 20.0 | 20.0 |
| Tiotropium Bromide Inhalation Spray | 10 | 12.8 | 12.8 |
| Sitagliptin And Metformin Hydrochloride | 18 | 12.0 | 12.0 |
| Ledipasvir And Sofosbuvir | 15 | 11.2 | 11.2 |
| Entecavir | 9 | 11.0 | 11.0 |
| Cisplatin | 57 | 10.7 | 10.8 |
| Everolimus Tablets | 12 | 10.2 | 10.3 |
| Febuxostat Tablets 40 Mg | 6 | 8.4 | 8.4 |
| Febuxostat Tablets 80 Mg | 6 | 8.4 | 8.4 |
| Trametinib | 13 | 7.7 | 7.7 |
| Liraglutide | 26 | 7.6 | 7.6 |
| Dabrafenib | 11 | 7.5 | 7.5 |
| Ivacaftor | 4 | 7.2 | 7.2 |
| Dutasteride | 4 | 7.0 | 7.0 |
| Oxaliplatin | 34 | 6.6 | 6.6 |
| Sofosbuvir | 9 | 6.5 | 6.5 |
| Panitumumab | 7 | 6.4 | 6.4 |
| Ustekinumab | 33 | 4.7 | 4.7 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 4 | 4.6 | 4.6 |
| Crizotinib | 4 | 4.5 | 4.5 |
| Velpatasvir And Sofosbuvir | 4 | 4.4 | 4.4 |
| Olaparib | 6 | 4.1 | 4.1 |
| Atezolizumab | 11 | 4.0 | 4.0 |
| Exenatide | 13 | 3.5 | 3.5 |
| Ranitidine Hydrochloride | 11 | 2.9 | 2.9 |
| Pirfenidone | 7 | 2.4 | 2.4 |
| Guselkumab | 6 | 2.4 | 2.4 |